- Conditions
- Urea Cycle Disorder
- Interventions
- KB195
- Drug
- Lead sponsor
- Kaleido Biosciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Tampa, Florida • Baltimore, Maryland + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 1,608
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Generalized Lipodystrophy
- Interventions
- Metreleptin
- Drug
- Lead sponsor
- Aegerion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • New Orleans, Louisiana • Ann Arbor, Michigan + 4 more
- Conditions
- Propionic Acidemia
- Interventions
- ornithine alpha ketoglutarate, glutamine, disodium citrate
- Drug
- Lead sponsor
- Nicola Longo
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Developmental Bone Disease, Dwarfism, Skeletal Dysplasias
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lactose Intolerance
- Interventions
- Not listed
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Achondroplasia
- Interventions
- Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 0 Years to 32 Months
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Oakland, California • Baltimore, Maryland • Madison, Wisconsin
- Conditions
- Hunter Syndrome
- Interventions
- Idursulfase-IT, Elaprase
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 3 Years to 18 Years · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2024
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Chapel Hill, North Carolina • Portland, Oregon + 4 more
- Conditions
- Maculopathy, Age-Related, Choroidal Neovascularization
- Interventions
- Not listed
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- PHP Ia, PHP IB, Php1C
- Interventions
- Theophylline
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 5 Years to 21 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2032
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- CAH - Congenital Adrenal Hyperplasia
- Interventions
- NBI-74788
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 3 more
- Conditions
- Pyruvate Dehydrogenase Complex Deficiency Disease
- Interventions
- No intervention
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- Not listed
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2030
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Argininosuccinic Aciduria, Carbamoyl-Phosphate Synthase I Deficiency, Citrullinemia, Ornithine Carbamoyltransferase Deficiency, Hyperargininemia, N-Acetylglutamate Synthase Deficiency
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 2 Years to 99 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Heart Diseases, Metabolism, Inborn Errors
- Interventions
- SCH-58235, Ezetimibe
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
- Interventions
- There is no intervention in this study
- Other
- Lead sponsor
- ProgenaBiome
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2030
- U.S. locations
- 1
- States / cities
- Ventura, California
- Conditions
- Pompe Disease (Late-onset)
- Interventions
- Cipaglucosidase Alfa, Miglustat
- Biological · Drug
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 0 Years to 17 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 9
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 6 more
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- exposure to healthcare transition protocol
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Gout, Hyperuricemia
- Interventions
- dotinurad, dotinurad + allopurinol, allopurinol
- Drug
- Lead sponsor
- Urica Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Clearwater, Florida • Miami Lakes, Florida • Mesquite, Texas + 1 more
- Conditions
- GM2 Gangliosidosis, Tay Sachs Disease, Sandhoff Disease
- Interventions
- AXO-AAV-GM2
- Drug
- Lead sponsor
- Terence Flotte
- Other
- Eligibility
- Not listed
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- ARG1 Deficiency
- Interventions
- Loargys Arginine Test System
- Device
- Lead sponsor
- Immedica Pharma US Inc
- Industry
- Eligibility
- 0 Years to 100 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Foscarnet sodium, Ganciclovir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1993
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Francisco, California • St Louis, Missouri + 3 more
- Conditions
- GM1 Gangliosidosis
- Interventions
- LYS-GM101
- Genetic
- Lead sponsor
- LYSOGENE
- Industry
- Eligibility
- Up to 3 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Acute Gout
- Interventions
- Canakinumab, Triamcinolone acetonide
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 27
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Buena Park, California + 23 more
- Conditions
- Phenylketonuria
- Interventions
- PTC923
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Gainesville, Florida • Indianapolis, Indiana + 4 more
- Conditions
- Gout
- Interventions
- placebo, BCX4208
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 24
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Irvine, California + 21 more